JP2021535161A5 - - Google Patents

Info

Publication number
JP2021535161A5
JP2021535161A5 JP2021510984A JP2021510984A JP2021535161A5 JP 2021535161 A5 JP2021535161 A5 JP 2021535161A5 JP 2021510984 A JP2021510984 A JP 2021510984A JP 2021510984 A JP2021510984 A JP 2021510984A JP 2021535161 A5 JP2021535161 A5 JP 2021535161A5
Authority
JP
Japan
Prior art keywords
hae
antibody
treatment period
weeks
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021510984A
Other languages
English (en)
Japanese (ja)
Other versions
JP7585193B2 (ja
JP2021535161A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/048961 external-priority patent/WO2020047352A1/en
Publication of JP2021535161A publication Critical patent/JP2021535161A/ja
Publication of JP2021535161A5 publication Critical patent/JP2021535161A5/ja
Priority to JP2024094996A priority Critical patent/JP7894905B2/ja
Application granted granted Critical
Publication of JP7585193B2 publication Critical patent/JP7585193B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021510984A 2018-08-30 2019-08-30 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 Active JP7585193B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024094996A JP7894905B2 (ja) 2018-08-30 2024-06-12 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862725216P 2018-08-30 2018-08-30
US62/725,216 2018-08-30
US201962808612P 2019-02-21 2019-02-21
US62/808,612 2019-02-21
PCT/US2019/048961 WO2020047352A1 (en) 2018-08-30 2019-08-30 Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024094996A Division JP7894905B2 (ja) 2018-08-30 2024-06-12 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用

Publications (3)

Publication Number Publication Date
JP2021535161A JP2021535161A (ja) 2021-12-16
JP2021535161A5 true JP2021535161A5 (cg-RX-API-DMAC7.html) 2022-09-05
JP7585193B2 JP7585193B2 (ja) 2024-11-18

Family

ID=67953889

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021510984A Active JP7585193B2 (ja) 2018-08-30 2019-08-30 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用
JP2024094996A Active JP7894905B2 (ja) 2018-08-30 2024-06-12 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024094996A Active JP7894905B2 (ja) 2018-08-30 2024-06-12 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用

Country Status (12)

Country Link
US (2) US20200109214A1 (cg-RX-API-DMAC7.html)
EP (1) EP3843840A1 (cg-RX-API-DMAC7.html)
JP (2) JP7585193B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210053928A (cg-RX-API-DMAC7.html)
CN (1) CN113056304A (cg-RX-API-DMAC7.html)
AU (2) AU2019328324B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021003789A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110689A1 (cg-RX-API-DMAC7.html)
IL (1) IL281063A (cg-RX-API-DMAC7.html)
MA (1) MA53490A (cg-RX-API-DMAC7.html)
MX (1) MX2021002349A (cg-RX-API-DMAC7.html)
WO (1) WO2020047352A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
KR102011156B1 (ko) 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
JP2016513682A (ja) 2013-03-15 2016-05-16 ダイアックス コーポレーション 抗血漿カリクレイン抗体
ES3065185T3 (en) 2014-01-21 2026-05-04 Takeda Pharmaceuticals Co Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
IL247942B (en) 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EP3843840A1 (en) * 2018-08-30 2021-07-07 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
AU2020392243A1 (en) 2019-11-28 2022-06-16 Regenxbio Inc. Microdystrophin gene therapy constructs and uses thereof
AU2021209045A1 (en) 2020-01-13 2022-07-28 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
CA2180950C (en) 1994-01-11 2005-03-29 William Markland Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
PT2298278E (pt) 2002-06-07 2016-02-25 Dyax Corp Prevenção e redução da perda de sangue e resposta inflamatória
KR102011156B1 (ko) * 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
JP2016513682A (ja) * 2013-03-15 2016-05-16 ダイアックス コーポレーション 抗血漿カリクレイン抗体
IL247942B (en) * 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
CA3290174A1 (en) * 2015-03-30 2026-03-02 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
US11286307B2 (en) * 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
JP6885952B2 (ja) * 2015-12-18 2021-06-16 グラコ ミネソタ インコーポレーテッド ベローズの取付けと保持方法
EP3843840A1 (en) * 2018-08-30 2021-07-07 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

Similar Documents

Publication Publication Date Title
JP2022033868A5 (cg-RX-API-DMAC7.html)
JP2019501886A5 (cg-RX-API-DMAC7.html)
US20240052058A1 (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
JP2024113183A5 (cg-RX-API-DMAC7.html)
JP2020002171A5 (cg-RX-API-DMAC7.html)
JP2022525164A5 (cg-RX-API-DMAC7.html)
TWI837532B (zh) 治療潰瘍性結腸炎之方法
JP2018514510A5 (cg-RX-API-DMAC7.html)
Reisch et al. Use of angiotensin-converting enzyme inhibitors for the preservation of kidney function
JP2019514974A5 (cg-RX-API-DMAC7.html)
JP2023527542A5 (cg-RX-API-DMAC7.html)
WO2023144699A1 (en) Methods for treatment of subjects with plaque psoriasis of the scalp
Takeuchi et al. OP0040 adding tocilizumab or switching to tocilizumab monotherapy in RA patients with inadequate response to methotrexate: 24-week results from a randomized controlled study (Surprise Study)
JP2022513029A5 (cg-RX-API-DMAC7.html)
JP2023510854A5 (cg-RX-API-DMAC7.html)
JP2021523138A5 (cg-RX-API-DMAC7.html)
KR20170118830A (ko) 조현병의 치료를 위한 일로페리돈
JP2024503379A5 (cg-RX-API-DMAC7.html)
WO2023137342A2 (en) Methods of treating al amyloidosis
JP2024522620A5 (cg-RX-API-DMAC7.html)
NZ783274B2 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
NZ783274A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
Dall'Era et al. FC 035 VOCLOSPORIN INCREASES RENAL RESPONSE AT COMMONLY USED UPCR THRESHOLDS IN PATIENTS WITH LUPUS NEPHRITIS
CA3035327C (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
US20210338766A1 (en) Methods of treating multiple myeloma